Project Grant F31DA065472
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of California, San Diego a $3.0M Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct translational and cross-species research examining the impact of cannabis use and HIV on mitochondrial homeostasis in brain macrophages. The five-year project, initiated June 1, 2026 and concluding April 30, 2031, combines clinical observational studies with preclinical cellular...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Children's Hospital of Philadelphia Research Institute a $456,268 Project Grant effective March 1, 2026, through February 29, 2028, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate antioxidant and cerebral blood flow profiles in individuals living with HIV (PWH) who use marijuana. The research employs advanced edited magnetic resonance spectroscopy (MRS) to measure brain glutathione...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $1.765 million Project Grant to the University of Alabama at Birmingham on April 15, 2026, with a completion date of January 31, 2031. This award funds research investigating the impact of cannabis use on T cell function and HIV (Human Immunodeficiency Virus) persistence within the central nervous system (CNS) reservoir. The research...
- Federal Project Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a Project Grant of $732,747 to Boston University Medical Campus on June 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports a research project titled "Quantifying Health Effects of Cannabis Use and Cannabis Use Disorder on Geriatric Syndromes and HIV Outcomes: Causal Effects Analysis in the Veterans Aging Cohort Study and the Mt. Sinai HIV Cohort,"...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $731,879 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 1, 2026 through February 28, 2031. This research project investigates the impact of recreational cannabis use on the NLRP3 inflammasome in people with HIV (PWH) compared to HIV seronegative individuals. The study addresses a critical gap in...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded a $496,402 Project Grant to the University of Colorado–Denver under the Drug Use and Addiction Research Programs (CFDA 93.279) on April 15, 2026, with completion targeted for March 31, 2028. This research initiative, titled "Advancing Cannabis Detection: Breath and Ocular Approaches," delivers rigorous independent validation of non-invasive cannabis impairment detection technologies to address public safety...
- Summary Drexel University received a $445,636 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), effective May 15, 2026 through February 28, 2031. The award supports research investigating neural circuit mechanisms underlying inflexible drug-seeking behavior in the context of Human Immunodeficiency Virus (HIV) infection. The project addresses a critical gap in therapeutic strategies for individuals living with...
- Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded Public Health Institute a $542,187 Project Grant (CFDA 93.279: Drug Use and Addiction Research Programs) on June 15, 2026, to conduct a three-year longitudinal research study examining cannabis use patterns among residents of sober living houses (SLHs). The study will recruit 35 SLHs and 400 residents (stratified into cannabis use and non-use groups) to assess the relationship between cannabis use and outcomes including...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This Project Grant award of $639,915, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research investigating the mechanistic underpinnings of cognitive inflexibility in offspring exposed prenatally to cannabis. The research, conducted at Washington State University in Pullman, Washington, and running through December 31, 2030, will deliver scientific knowledge regarding how prenatal cannabis exposure affects...
IMPACT OF CANNABIS USE ON VISUAL FUNCTIONING AND VISUOSPATIAL NEUROPSYCHOLOGICAL PERFORMANCE IN CANNABIS USERS WITH AND WITHOUT HIV - PROJECT SUMMARY/ABSTRACT RATES OF HIV INFECTION AND CANNABIS USE ARE SIMULTANEOUSLY INCREASING IN THE UNITED STATES. ADDITIONALLY, PEOPLE LIVING WITH HIV (PLWH) ARE SUBSTANTIALLY MORE LIKELY TO REPORT CANNABIS USE THAN THE GENERAL POPULATION. SEPARATELY, HIV AND CANNABIS USE ARE ASSOCIATED WITH DECLINES IN MULTIPLE COGNITIVE DOMAINS INCLUDING MEMORY, ATTENTION, AND EXECUTIVE FUNCTIONS, AS WELL AS POORER VISUAL FUNCTIONS INCLUDING CONTRAST SENSITIVITY AND VISUAL ACUITY. HOWEVER, FEW STUDIES HAVE EXPLORED THE INDIVIDUAL AND COMBINED EFFECTS OF HIV AND CANNABIS USE ON GRANULAR TESTS OF VISUOSPATIAL COGNITION (I.E., OUTSIDE OF VISUAL MEMORY) OR VISUAL FUNCTIONING. GIVEN THAT SPECIFIC VISUAL ABILITIES (E.G., PERCEPTION OF ANGULAR RELATIONSHIPS, VISUAL ORGANIZATION, USEFUL FIELD OF VIEW; CONTRAST SENSITIVITY, VISUAL ACUITY) HAVE DEMONSTRABLE PREDICTABILITY REGARDING REAL-WORLD DRIVING PERFORMANCE, IT IS CRITICAL TO EXPLORE THESE FUNCTIONS IN POPULATIONS OF CANNABIS USERS WITH AND WITHOUT HIV. BEYOND RESEARCH FINDINGS, ASSESSMENT OF VISUAL FUNCTIONING AND VISUOSPATIAL COGNITION MAY BE CLINICALLY-USEFUL PREDICTORS OF TRAFFIC SAFETY IN THESE POPULATIONS. THE OVERARCHING GOAL OF THE PROPOSED F31 IS TO DETERMINE IF CANNABIS USE PATTERNS AND HIV DISEASE CHARACTERISTICS PREDICT POORER PERFORMANCE ON THESE TESTS, AS WELL AS ASSOCIATED EVERYDAY FUNCTIONING (E.G., DRIVING SIMULATOR PERFORMANCE). THE AIMS ARE TO 1) EXAMINE PERFORMANCE ON VISUOSPATIAL NEUROPSYCHOLOGICAL ASSESSMENTS SUGGESTED TO PREDICT DRIVING SAFETY IN CANNABIS USERS WITH AND WITHOUT HIV AND 2) EXAMINE THE IMPACT OF CANNABIS USE PATTERNS ON CONTRAST SENSITIVITY AND VISUAL ACUITY IN CANNABIS USERS WITH AND WITHOUT HIV. ADDITIONALLY, EXPLORATORY ANALYSES WILL PROBE WHETHER THE ACUTE USE OF INCREASINGLY AVAILABLE HIGH-THC CONCENTRATES PRODUCES DECREMENTS IN CONTRAST SENSITIVITY AND DRIVING SIMULATOR PERFORMANCE IN HEALTHY ADULT CONCENTRATE USERS COMPARED TO A NON-USING CONTROL GROUP, INFORMING POSSIBLE FUTURE STUDIES IN INDIVIDUALS WITH HIV. THIS PROJECT WILL UTILIZE ARCHIVAL NEUROPSYCHOLOGICAL, VISUAL ACUITY, AND CONTRAST SENSITIVITY DATA COLLECTED FROM UC SAN DIEGO'S HIV NEUROBEHAVIORAL RESEARCH PROGRAM AND CENTER FOR MEDICINAL CANNABIS RESEARCH. CRITICALLY, THE TRAINING OPPORTUNITIES PROVIDED BY THE F31 FUNDING MECHANISM WILL FACILITATE THE APPLICANT'S LONG-TERM GOAL OF BECOMING AN INDEPENDENT ACADEMIC NEUROPSYCHOLOGIST WITH A FOCUS ON ELUCIDATING REAL-WORLD AND DRIVING-RELEVANT NEUROPSYCHOLOGICAL OUTCOMES ASSOCIATED WITH CANNABIS USE IN HEALTHY AND CLINICAL POPULATIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $576 | 3/25/26 | ||
| Not listed | $47.0k | 2/20/26 | ||
| Not listed | $47.0k | 2/20/26 |